An orally bioavailable small molecule antagonist of VISTA and VSIG8 signaling pathways shows potent anti-tumor activity

被引：0
|
作者：
Sasikumar, Pottayil [1 ]
Naremaddepalli, Sudarshan [1 ]
Ramachandra, Raghuveer [1 ]
Gowda, Nagesh [1 ]
Alluri, Govardhan [1 ]
Yerramsetti, Manikyalarao [1 ]
Adurthi, Sreenivas [1 ]
Mani, Jiju [1 ]
Nair, Rashmi [1 ]
Dhudashiya, Amit [1 ]
Dodheri, Samiulla [1 ]
Gowda, Nagaraj [1 ]
Ramachandra, Murali [1 ]
机构：
[1] Aurigene Discovery Technol Ltd, Bangalore, Karnataka, India
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P354
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ANTI-TUMOR ACTIVITY OF CB-668, A POTENT, SELECTIVE AND ORALLY BIOAVAILABLE SMALL-MOLECULE INHIBITOR OF THE IMMUNO-SUPPRESSIVE ENZYME INTERLEUKIN 4 (IL-4)-INDUCED GENE 1 (IL4I1)
    MacKinnon, Andrew
    Bhupathi, Deepthi
    Chen, Jason
    Huang, Tony
    Li, Weiqun
    Ma, Yong
    Sotirovska, Natalija
    Steggerda, Susanne
    Zhang, Winter
    Parlati, Francesco
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A423 - A424
  • [42] Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis
    Flaveny, Colin A.
    Griffett, Kristine
    El-Gendy, Bahaa El-Dien M.
    Kazantzis, Melissa
    Sengupta, Monideepa
    Amelio, Antonio L.
    Chatterjee, Arindam
    Walker, John
    Solt, Laura A.
    Kamenecka, Theodore M.
    Burris, Thomas P.
    CANCER CELL, 2015, 28 (01) : 42 - 56
  • [43] Anti-tumor activity of novel small molecule inhibitors of mixed protein kinases.
    Narla, RK
    Stein, B
    Ezell, C
    Mortensen, D
    Raymon, HK
    Gamez, J
    Sapienza, J
    Wright, J
    Hughes, K
    Fultz, K
    Delgado, M
    Boluro-Ajayi, M
    Shirley, MA
    Khatsenko, O
    Pai, S
    Clareen, S
    Bhagwat, S
    Sakata, S
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6243S - 6243S
  • [44] Targeting Notch and Hedgehog Embryonic Signaling Pathways Has Potent Anti-Tumor Activity in Myeloma and Is Effective in Myeloma Bone Disease.
    Schwarzer, Rolf
    Schuenemann, Nicole
    Wong, David M.
    Bogen, Bjarne
    Bommert, Kurt
    Doerken, Bernd
    Manz, Rudolf
    Jundt, Franziska
    BLOOD, 2012, 120 (21)
  • [45] Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways
    Peng, Xuerun
    Shi, Jianyou
    Zhao, Zhipeng
    Tong, Rongsheng
    Zhang, Xiaonan
    Zhong, Lei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (04) : 303 - 315
  • [46] Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways
    Xuerun Peng
    Jianyou Shi
    Zhipeng Zhao
    Rongsheng Tong
    Xiaonan Zhang
    Lei Zhong
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 303 - 315
  • [47] AUR103 an oral small molecule CD47 antagonist in combination with azacytidine and bortezomib exhibits potent anti-tumor activity in myeloma and leukemia models in vitro and in vivo
    Daginakatte, Girish C.
    Pottayil, Sasikumar
    Naremaddepalli, Sudarshan
    Chennakrishnareddy, Gundala
    Bilugudi, Prasad
    Tangella, Sai Krishna
    Patil, Sandeep
    Gowda, Nagesh
    Aithal, Kiran
    Balasubramanian, Wesley Roy
    Dhudashiya, Amit
    Dodheri, Samiulla
    Nellore, Kavitha
    Samajdar, Susanta
    Ramachandra, Murali
    CANCER RESEARCH, 2022, 82 (12)
  • [48] BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows potent anti-tumor activity as a single agent and in combination with standard of care therapies in preclinical tumor models
    Lundgren, K.
    Timple, N.
    Ibanez, G.
    Yang, C.
    Neely, L.
    Kamal, A.
    Hong, K.
    Zhang, H.
    EJC SUPPLEMENTS, 2008, 6 (12): : 50 - 50
  • [49] The novel aurora kinase inhibitor AS703569 shows potent anti-tumor activity in acute myeloid leukemia (AML).
    Sarno, Samantha
    Shaw, Jamie
    Spooner, Edward
    Ma, Jianguo
    Clark, Ann
    Dumontet, Charles
    Romanelli, Angela
    BLOOD, 2007, 110 (11) : 279A - 279A
  • [50] PDL192, a novel, humanized antibody to TWEAK receptor, shows potent anti-tumor activity in preclinical models
    Culp, P.
    Choi, D.
    Yin, J.
    Tan, S.
    Chao, D.
    Su, M.
    Sho, M.
    Steinte, R.
    Hsi, E.
    Ramakrishnan, V.
    EJC SUPPLEMENTS, 2008, 6 (12): : 161 - 161
12345